Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.
Stock data | 2024 | Change |
---|---|---|
Price | $3.93 | N/A |
Market Cap | $445.69M | N/A |
Shares Outstanding | 113.34M | N/A |
Employees | 0 | N/A |